Ewing's sarcoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Michael Maddaleni, B.S.

Ewing's sarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Ewing's sarcoma from other diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Biopsy
X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Ewing's sarcoma pathophysiology On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Ewing's sarcoma pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ewing's sarcoma pathophysiology
CDC on Ewing's sarcoma pathophysiology
Ewing's sarcoma pathophysiology in the news
Blogs on Ewing's sarcoma pathophysiology
Directions to Hospitals Treating Ewing's sarcoma
Risk calculators and risk factors for Ewing's sarcoma pathophysiology

Overview

Ewing's sarcoma is the result of a translocation between chromosomes 11 and 22, which fuses the EWS gene of chromosome 22 to the FLI1 gene of chromosome 11.

Histology

The composition of Ewing's sarcoma consists of a homogeneous population of small round cells that have a high nuclear to cytoplasmic ratio. Also, the population of small round cells are arrayed in sheets. There is a presence of scant cytoplasms which are pale, vacuolated, and are characterized by their faded boundaries. The nuclei have intense color which make them easily visible. Mitotic activity is usually low within these cells, and cytoplasmic glycogen is also usually present.